Complete title: A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults with Acute Lymphoblastic Leukemia/Lymphoma
Research Study Number | 9770 |
Principal Investigator | Ryan Cassaday |
Phase | II |
Other eligibility criteria may apply.
Research Study Number | 9770 |
Contact | Seattle Cancer Care Alliance Intake Office |
Telephone | 800-804-8824 / 206-606-1024 |
Keywords: Leukemia, Acute Lymphoblastic (ALL); Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin (NHL); Leukemia, Lymphoid; Immunoproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Immune System Diseases; Lymphoma, Lymphoblastic (LBL)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.